Articles tagged "Dosage"

2018 American Transplant Congress
Innovative Strategies to Accommodate Increased Patient Volume in an Outpatient Transplant Infusion Center
J. Estrada, M. Tyrell, J. Choi, J. Jagolino, S. Jordan.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
Purpose: To accommodate the increasing volume of patients scheduled for infusions at the Comprehensive Transplant Center(CTC) Infusion suite. It began as a two chair unit…
2018 American Transplant Congress
Genome-Wide Association Study of Tacrolimus Dose in Pediatric Solid Organ Transplant Recipients in the CNTRP POSITIVE Study
S. Min,¹ T. Papaz,¹ T. Blydt-Hansen,³ O. Lee,¹ U. Allen,¹ P. Birk,² H. Grasemann,¹ L. Hamiwka,⁴ C. Litalien,⁵ V. Ng,¹ R. Parekh,¹ K. Tinckam,⁶ S. Urschel,⁷ B. Foster,⁸ S. Mital.¹
¹The Hospital for Sick Children, Toronto, Canada; ²Winnipeg Children's Hospital, Winnipeg, Canada; ³BC Children's Hospital, Vancouver, Canada; ⁴Alberta Children's Hospital, Calgary, Canada; ⁵CHU Ste-Justine, Montreal, Canada; ⁶University Health Network, Toronto, Canada; ⁷Stollery Children's Hospital, Edmonton, Canada; ⁸Montreal Children's Hospital, Montreal, Canada.
PURPOSE: There are significant challenges in achieving therapeutic tacrolimus (Tac) concentrations after transplant. We explored variants associated with tacrolimus dose requirements in pediatric solid organ…
2018 American Transplant Congress
Cytomegalovirus Prophylaxis Following Alemtuzumab Induction in High Risk Renal Transplant Recipients Experiencing Delayed Graft Function
S. Freedman, B. Ravichandran, B. Masters, E. Heil, K. Saharia, J. Bromberg, A. Haririan, T. Sparkes.
University of Maryland, Baltimore.
Purpose: There is limited data to support the use of valganciclovir in patients on dialysis. This study assessed the efficacy of valganciclovir 450 mg twice…
2018 American Transplant Congress
A Review of Pediatric Drug Development Programs and FDA Labeling for Immunosuppressive Drugs in Organ Transplant Patients
G. Burckart,¹ M. Cavaillé-Coll,² A. Duong,³ L. Hothem,⁴ R. Albrecht.²
¹Office of Clinical Pharmacology, Office of Translational Science, CDER, US Food and Drug Administration, Silver Spring, MD; ²Division of Transplant and Opthalmology Products, Office of New Drugs, CDER, US Food and Drug Administration, Silver Spring, MD; ³Tauro University, New York, NY; ⁴University of North Carolina, Chapel Hill, NC.
The development of drugs for organ transplantation spanned the time before and after pediatric regulatory requirements under the Best Pharmaceuticals for Children Act (BPCA) and…
2018 American Transplant Congress
Does One Size Fit All? Implementing a Protocolized Ambulatory Tacrolimus Dosing Strategy in a Predominantly African American Renal Transplant Population
L. Gylten, C. Mardis, D. Taber, H. Meadows, C. Perez, Z. Elmaasarani, J. Fleming, N. Patel, P. Baliga, V. Rao, V. Rohan, N. Pilch.
Medical University of South Carolina, Charleston, SC.
Introduction: African American (AA) KTx recipients have significant tacrolimus (FK) inter patient variability making protocolized dosage adjustment challenging. We sought to evaluate the efficacy &…
2018 American Transplant Congress
Evaluation of Tacrolimus Extended-Release in African American Renal Transplant Recipients
T. Sparkes, B. Ravichandran, C. Williams, B. Thomas, B. Masters.
University of Maryland, Baltimore.
Purpose: Limited data exists to guide appropriate dosing strategies for novel tacrolimus formulations, such as tacrolimus XL (Astagraf XL). This is especially true in the…
2018 American Transplant Congress
Itraconazole Prophylaxis, Trough Concentration, and Identification of Fungal Pathogens in Lung Transplant
H. Hassouna, V. Athans, K. Brizendine.
Cleveland Clinic Foundation, Cleveland, OH.
Studies of prophylactic itraconazole (ITR) in lung transplant recipients (LTR) are lacking. Our purpose was to evaluate LTR who received ITR prophylaxis and the association…
2017 American Transplant Congress
The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing.
K. Flabouris,^1,2 S. Chadban,^1,3,4 M. Ladhani,^1,3,5 M. Cervelli,⁶ P. Clayton.^1,2,6
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia; ²School of Medicine, University of Adelaide, Adelaide, Australia; ³Sydney Medical School, University of Sydney, Sydney, Australia; ⁴Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ⁵Department of Renal Medicine, Lyell McEwin Hospital, Adelaide, Australia; ⁶Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia
Purpose: High body mass index (BMI) is associated with acute rejection after kidney transplantation. We hypothesised that weight-adjusted immunosuppression dosing is a contributing factor. We…
2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
I. Ashoor,¹ K. Martz,² R. Beyl,³ V. Dharnidharka.⁴
¹Children's Hospital, New Orleans, LA; ²EMMES Corporation, Rockville, MD; ³Pennington Biomedical Research Center, Baton Rouge, LA; ⁴Washington University, St. Louis, MO
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…
2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
M. Alfares, R. Avery, N. Turki, K. Alfares, S. Mehta, R. Boger, A. Valsamakis.
Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Transplant & Oncology Infectious Disease, Johns Hopkins, Baltimore, MD; Pediatric Infectious Disease, Johns Hopkins, Baltimore, MD; Pathology, Johns Hopkins, Baltimore, MD
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…